Certara, Inc. (HAM:700)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.28B -21.7% |
| Revenue (ttm) | 369.15M +11.1% |
| Net Income | -59.87M |
| EPS | -0.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 23.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 8.41 |
| Previous Close | 8.51 |
| Day's Range | 8.41 - 8.52 |
| 52-Week Range | 3.74 - 8.85 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Certara
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial numbers in USD Financial StatementsNews
Certara price target raised to $11 from $9 at TD Cowen
TD Cowen raised the firm’s price target on Certara (CERT) to $11 from $9 and keeps a Buy rating on the shares. The firm adjusted targets in the life science…
Certara price target raised to $9 from $7.50 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Certara (CERT) to $9 from $7.50 and keeps an Equal Weight rating on the shares. The firm adjusted targets in…
Certara resumed with a Neutral at UBS
UBS resumed coverage of Certara (CERT) with a Neutral rating and $10 price target UBS assumed coverage of the contract research organization industry with a constructive view on fundamentals, citing…
Certara price target raised to $7 from $6 at Baird
Baird raised the firm’s price target on Certara (CERT) to $7 from $6 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Certara price target lowered to $9 from $10 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Certara (CERT) to $9 from $10 and keeps an Equal Weight rating on the shares.
Certara price target raised to $7.50 from $6.50 at Barclays
Barclays raised the firm’s price target on Certara (CERT) to $7.50 from $6.50 and keeps an Equal Weight rating on the shares.
Certara Earnings Call Transcript: Q2 2026
Q2 2026 saw 1% revenue growth, with software up 4% and services down 3%. Guidance for 2026 remains at 0%–4% revenue growth, with software expected to outperform. Strategic actions included a divestiture, cost reductions, and new leadership, while AI integration and international expansion are driving future growth.
Certara Earnings release: Q2 2026
Certara released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Certara Quarterly report: Q2 2026
Certara has published its Q2 2026 quarterly earnings report on August 4, 2026.
Certara Slides: Q2 2026
Certara has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Certara backs FY26 adjusted EPS view 31c-36c, consensus 38c
Backs Fy26 revenue view $367M-$382M, consensus $398.63M. The company said, “Certara (CERT) is reaffirming its revenue growth and updating its adjusted EBITDA margin, adjusted diluted earnings per shar...
Certara reports Q2 adjusted EPS 8c, consensus 9c
Reports Q2 revenue $93.3M, consensus $98.08M. “This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara (CERT) int...
Certara Reports Second Quarter 2026 Financial Results
Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 ...
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q...
Certara partners with Nvidia to advance open integrated AI platform
Certara (CERT) is partnering with Nvidia (NVDA) to advance Certara’s open integrated AI platform. The Nvidia BioNeMo provides access to Nvidia’s full life science stack. Within Certara’s platform, Bio...
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platf...
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's execu...
Certara announces CFO transition; affirms FY26 guidance
Certara (CERT) “announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end of the day on…
Certara Announces CFO Transition
RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified th...
Leerink says Certara peer acquisition supports higher multiple
Leerink sees Certara’s (CERT) valuation as overly depressed given what remains a highly profitable entity with multiple long-term growth drivers. This morning’s acquisition of peer Simulations Plus (S...
Certara Transcript: Jefferies Global Healthcare Conference 2026
The company has realigned into two strategic segments, ACE and MID3, to drive growth and operational clarity. AI is being integrated across all products, with a focus on leveraging regulatory expertise and data assets. Strong software growth, ongoing R&D investment, and regulatory tailwinds support expansion in both small and large molecule markets.
Certara Transcript: RBC Capital Markets Global Healthcare Conference 2026
Leadership emphasized deep scientific expertise and a flexible business model, with AI integration and regulatory trends driving growth. Positive biotech funding and regulatory tailwinds support robust demand, while operational changes and cost actions aim to deliver double-digit growth and stable margins by 2026.
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followin...
Certara Transcript: AGM 2026
The meeting saw the re-election of three directors, ratification of the auditor, and approval of executive compensation. Shareholders participated virtually, and all proposals passed by majority vote. Voting results will be filed with the SEC.
Certara price target lowered to $6 from $7 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Certara (CERT) to $6 from $7 and keeps a Market Perform rating on the shares. The company’s Q1 results…